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AbsTrACT
Objective To describe the clinicopathological and 
genomic features of nine patients with primary and 
secondary orbital/ocular manifestations of leukaemia.
Methods All orbital/ocular leukaemic specimens from 
1980 to 2009 were collected from the Danish Register 
of Pathology. In six cases, medical records and formalin-
fixed, paraffin-embedded blocks were available. Three 
cases from the Department of Pathology, Royal Liverpool 
University Hospital, were also included. Immunophenotypes 
and MYB oncoprotein expression were ascertained 
by immunohistochemistry. Genomic imbalances were 
analysed with comparative genomic hybridisation arrays 
and oncogene rearrangements with fluorescence in situ 
hybridisation.
results Four patients had B-cell precursor acute 
lymphoblastic leukaemia (BCP-ALL) and five had acute 
myeloid leukaemia (AML). Two patients with BCP-ALL 
and one with AML had primary orbital manifestations 
of leukaemia. Common symptoms were proptosis, 
displacement of the eye, and reduced eye mobility in 
patients with orbital leukaemias and pain, and reduced 
visual acuity in patients with ocular leukaemias. All 
patients with primary orbital lesions were alive up to 18 
years after diagnosis. All but one patient with secondary 
ophthalmic manifestations died of relapse/disseminated 
disease. ETV6 and RUNX1 were rearranged in BCP-
ALL, and RUNX1 and KMT2A in AML. Genomic profiling 
revealed quiet genomes (0–7 aberrations/case). The MYB 
oncoprotein was overexpressed in the majority of cases.
Conclusions Leukaemias with and without ophthalmic 
manifestations have similar immunophenotypes, 
translocations/gene fusions and copy number alterations. 
Awareness of the clinical spectrum of leukaemic lesions of 
the eye or ocular region is important to quickly establish 
the correct diagnosis and commence prompt treatment.
InTrOduCTIOn
Leukaemic infiltrates can occur in the eye 
or ocular region as a primary manifestation 
of leukaemia or as an infiltration of systemic 
disease.1 2 Ophthalmic manifestations are 
more common in acute leukaemias than 
in chronic leukaemias.1 3 Typical symptoms 
of patients with leukaemic infiltrates in the 
ophthalmic region include eyelid oedema and 
swellings, chemosis and exophthalmos. Globe 
displacement by a leukaemic mass may restrict 
ocular mobility and in some cases reduce 
visual acuity.4 Orbital tumours may present as 
a diffuse infiltrate or as a large single mass. 
Solid infiltrates can involve all structures in 
the extraocular region, including the ocular 
adnexa and the optic nerve,4–6 and constitute 
approximately 2% of all malignancies in this 
region.5
Intraocular manifestations of leukaemias 
are most frequently seen clinically in the 
retina, but on histopathological examination, 
leukaemic lesions of the choroid are equally 
as common.4 6 Patients with intraocular 
Key message
What is already known about this subject?
 ► Leukaemic infiltrates may occur in the eye or ocu-
lar region, and in rare cases it is the first presenting 
symptom of leukaemia.
 ► Leukaemias with ophthalmic manifestations are 
rarely biopsied or examined extensively, and there-
fore our knowledge about these lesions is limited.
What are the new findings?
 ► This is the first comprehensive, integrated clinico-
pathological, cytogenetic and genomic analyses of 
acute leukaemias with ophthalmic manifestations.
 ► We show for the first time that leukaemias with eye 
and/or ocular manifestations have similar genetic 
and molecular profiles compared with other non–
site-specific leukaemias.
How might these results change the focus of 
research or clinical practice?
 ► Our findings further emphasise the broad clinical 
spectrum of leukaemic lesions with ophthalmic 
manifestations and the need to consider leukaemia 
in the differential diagnosis of patients with propto-
sis, reduced mobility and/or displacement of the eye.
 ► Awareness of the clinical spectrum of leukaemic 
lesions of the eye or ocular region is important to 
quickly establish the correct diagnosis and com-
mence prompt treatment.
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leukaemic manifestations often have reduced vision, and 
occasionally also pain or decreased mobility of the eye. 
Retinal detachment, chemosis, retinitis, glaucoma, uveitis 
or hypopyon are observed on clinical examination.4 6
Ophthalmic signs and symptoms may also result from 
side effects associated with leukaemia, such as anaemia, 
thrombocytopenia, hyperviscosity, immunosuppression 
and infections.1 4 6 When a primary leukaemia arises in 
the eye or ocular adnexa, subsequent involvement of the 
peripheral blood or bone marrow usually occurs within 
1 year of the ocular disease.7
Leukaemias with ophthalmic manifestations are rarely 
biopsied or examined extensively,1 5 and therefore our 
knowledge about these lesions is still limited. In this 
study, we describe in detail the clinical, cytogenetic, and 
genomic features of nine cases of primary and secondary 
ophthalmic leukaemias.
MATerIAls And MeTHOds
Patient material
All cases of ocular and ocular adnexal leukaemic lesions 
from 1980 to 2009 were collected from the Danish 
Register of Pathology. In six cases, medical records and 
formalin-fixed, paraffin-embedded (FFPE) tissue blocks 
were available. Also included were three leukaemias 
with ophthalmic manifestations from the Department of 
Pathology, Royal Liverpool University Hospital, UK. The 
following information was collected from the patients’ 
medical records: age, sex, diagnosis, histopathological 
findings, cytogenetic data, molecular genetic data (when 
available), location of the lesion, symptoms, treatment 
and clinical follow-up.
Histopathology and immunohistochemistry
The orbital and ocular biopsies were evaluated on 
sections stained with H&E and periodic acid-Schiff. For 
immunohistochemistry, FFPE tissue blocks were cut into 
sections 4 µm thick and mounted on slides. Stains were 
performed using the streptavidin–biotin method. Anti-
bodies against CD3, CD10, CD13, CD15, CD20, CD33, 
CD34, CD43, CD45, CD79α, CD117, MPO, TLC1, BCL-2, 
TdT and lysozyme were used in most cases. The expres-
sion of the MYB oncoprotein (SPM-175; Santa-Cruz, 
Dallas, Texas, USA) was studied as described.8 Samples 
were scored as MYB positive when >25% of the neoplastic 
cells stained positive for MYB. Negative and positive 
controls were included in all stains, and internal positive 
controls were evaluated where appropriate. For analyses 
of immunostainings, positive tumour cells were counted 
in five high-power fields (×400).
Array comparative genomic hybridisation (arrayCGH) analysis
Genomic DNA from FFPE blocks was isolated with 
the DNeasy Blood and Tissue Kit (Qiagen, Hilden, 
Germany). In seven cases, there was enough DNA avail-
able for arrayCGH analysis with Human Genome CGH 
Microarray 244K oligonucleotide arrays (Agilent Tech-
nologies, Santa Clara, California, USA).8 Data were 
analysed with NEXUS Copy Number V.7.0 Discovery 
Edition (BioDiscovery, El Segundo, California, USA).8 
The settings for aberration calls were 1.5 for amplifica-
tion, 0.3 for gain, –0.3 for loss and –1.5 for homozygous 
deletion. The FASST2 segmentation algorithm was used 
to define non-random regions of copy number alterations 
(CNAs) across the genome at a significance threshold of 
p=1.0E−8. In samples from cases 2 and 5, the settings for 
aberration calls were 1.5 for amplification, 0.5 for gain, 
–0.5 for loss and –1.5 for homozygous deletion at a signif-
icance threshold of p=1.0E−18. The accuracy of each 
aberration call was confirmed manually.
Fluorescence in situ hybridization (FIsH)
Rearrangements of ETV6 and KMT2A were analysed on 
5 µm FFPE sections with FISH dual-colour break probes 
(Leica Biosystems, Wetzlar, Germany). The protocols 
for pre-treatment, hybridisation and post-hybridisation 
washes were as recommended by the manufacturer. Fluo-
rescence signals were digitised, processed and analysed 
with the Isis FISH imaging system V.5.5 (MetaSystems, 
Altlussheim, Germany). At least 50 nuclei were scored for 
each probe and case.
Patient and public involvement
Patients and the public were not involved in the design, 
conduct and reporting of the research. However, permis-
sion was obtained to include photographs of two of the 
patients in the publication.
resulTs
Clinical characteristics of primary ophthalmic leukaemias
We identified three cases of acute leukaemias with primary 
ophthalmic manifestations in the Danish Register of 
Pathology from 1980 to 2009. The clinical, cytogenetic 
and molecular genetic findings are summarised in 
table 1.
Case 1 was an otherwise healthy 5-year-old boy with 
left-sided exophthalmos, a swollen lacrimal gland 
and a bluish-red discolouration of the eyelid. The eye 
examination, including visual acuity, was normal. A 
CT scan showed a homogeneous mass in the left orbit 
and displacement of the optic nerve. The lateral rectus 
muscle was surrounded by neoplastic tissue. Physical 
examination revealed enlarged lymph nodes on the neck 
and testis. Analysis of peripheral blood showed anaemia, 
and bone marrow and testis biopsies revealed lympho-
blastic leukaemia cells positive for CD3, CD10 and 
CD79α. The cellular morphology and immunoprofile 
were consistent with BCP-ALL. The patient responded 
well to chemotherapy (NOPHO ALL-92 protocol) and 
was still in complete remission at the last follow-up, 13 
years after diagnosis.
Case 2 was a 9-year-old girl with swelling and redness of 
the left eyelid. Her visual acuity was normal, but she had 
ptosis and decreased mobility of the eyelid (figure 1A). 
The patient was initially treated with antibiotics, but the 
lesion continued to enlarge. A preauricular lymph node 
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Figure 1 (A) 9-year-old girl (case 2) with left-sided proptosis, discolouration of the upper eye lid and ptosis. (B) Patient in (A) 
after 2 months of treatment. (C) 1-year-old boy (case 5) with left-sided proptosis and oedema of both eyelids. (D) MRI scan of 
the orbits (coronal view) of the patient in (C) shows a homogeneous mass involving the inferior half of the left orbit (asterisk).
and several submandibular nodes were swollen. The 
eyeball was displaced downward and medially. A CT scan 
revealed a mass in the superior orbital region involving 
the eyelid. A bone marrow biopsy showed infiltration of 
malignant lymphoblastic cells positive for CD10, CD20, 
CD79α, CD43, TdT and BCL-2. The cellular morphology 
and immunoprofile were consistent with BCP-ALL. She 
responded well to chemotherapy (NOPHO ALL 2000 
protocol) (figure 1B) and was still in complete remission 
at the latest follow-up, 5 years after diagnosis.
Case 5 was a 1-year-old boy with fever and left-sided 
proptosis of a few weeks’ duration. He had oedema of 
both eyelids, bluish discolouration of the inferior lid and 
proptosis (4 mm) (figure 1C). CT and MRI showed a large 
homogeneous mass involving the inferior half of the left 
orbit, extending from the inferior lid to the orbital apex 
(figure 1D). Orbital and bone marrow biopsies revealed 
leukaemic infiltrates with neoplastic cells positive for 
Sudan black B, lysozyme, CD43 and CD45. The micro-
scopic findings and the immunoprofile were consistent 
with AML, FAB type M5. Blood analysis showed pancy-
topenia. The patient had several blood transfusions and 
received chemotherapy (NOPHO AML 1993 protocol). 
He is still in remission, 18 years after diagnosis.
None of the three paediatric patients with primary 
orbital presentation of disease had any evidence of 
leukaemic infiltrates in the retina or choroid.
Clinical characteristics of secondary ophthalmic leukaemias
Six patients were diagnosed with systemic leukaemia 
before ophthalmic symptoms were present. Orbital/
ocular manifestations were evident at a mean age of 
49.2 years (range, 17–70 years). The leukaemic lesions 
were bilateral in one case, affected the left eye in three 
cases and the right eye in two. The average duration 
of symptoms before medical consultation was 5 weeks 
(range, 2–9 weeks). All patients with orbital tumours 
had proptosis, displacement of the eye and restricted 
eye mobility. Two patients with ocular manifestations had 
leukaemic infiltrates in the retina and subretinally; one 
of these patients also had involvement of the uvea and 
infiltration of the optic nerve. Two additional patients 
had infiltrates in the choroid, iris and anterior segment. 
Two patients with ocular lesions had pain from the eye; 
one also had blurred vision, and an examination revealed 
a visual acuity of 0.25, vitreous haze and papilloedema. 
One patient had a palpable mass. The lesions were diag-
nosed as BCP-ALL in two cases (figure 2A, B) and AML 
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Figure 2 (A) Lymphoblastic cells with irregular nuclei and 
sparse cytoplasm infiltrating the iris (H&E staining) in a 
patient with B-cell precursor acute lymphoblastic leukaemia 
(case 4); (B) lymphoblastic cells from case 4 are strongly 
immunoreactive for terminal deoxynucleotidyl transferase 
(TdT); (C) myeloblastic cells with an eosinophilic cytoplasm 
and indistinct cell boundaries and lymphocytes infiltrating 
the orbital fat tissue (H&E staining) in a patient with acute 
myeloid lekaemia Fab M1 (case 7); (D) myeloblastic 
cells from case 7 are strongly immunoreactive for 
myeloperoxidase; (E–H) expression of the MYB oncoprotein 
in ophthalmic leukaemic lesions from case 1, B-cell 
precursor acute lymphoblastic leukaemia (E), case 2, B-cell 
precursor acute lymphoblastic leukaemia (F), case 5, acute 
myeloid leukaemia Fab M5 (G), and case 7, acute myeloid 
leukaemia Fab M1 (H).
in three (figure 2C, D); one patient had a history of 
chronic lymphocytic leukaemia (CLL) with high-grade 
transformation to AML (table 1). All six patients received 
chemotherapy; two patients also received allogeneic bone 
marrow transplants, and two had radiotherapy. Four of 
the six patients died of relapse and/or disseminated 
disease 4–36 months after the onset of eye symptoms, 
one died of disseminated disease an unknown number of 
months after diagnosis and one died of heart failure 1.5 
years after relapse.
expression of the MYb oncoprotein
Two of the three analysed BCP-ALLs showed strong 
nuclear immunostaining for the MYB oncoprotein in 
the majority of leukaemic cells (table 1 and figure 2E, 
F). Three of four analysed AML samples also had strong 
nuclear staining in the majority of neoplastic cells 
(table 1 and figure 2G, H). The MYB oncoprotein was 
not expressed in one BCP-ALL (case 3) and one AML 
(case 9).
Cytogenetic and molecular genetic characteristics
Cytogenetic information was available from three 
patients with BCP-ALL and four with AML. The karyo-
typic alterations are shown in table 1. Two of the three 
ALLs had abnormal karyotypes, and one had no cytoge-
netic changes (case 4). Case 2 had the classical t(12;21)
(p13;q22) translocation associated with paediatric 
BCP-ALL, whereas case 1 had an uncommon t(2;3)
(p11;q29) seen in a small subset of BCP-ALL. The case 
with the t(12;21) had a rearrangement of ETV6 consis-
tent with an ETV6–RUNX1 gene fusion. FISH analysis also 
revealed an ETV6 rearrangement in case 3 (figure 3A); 
case 1 had no evidence of ETV6 rearrangement. Similarly, 
three of the four AMLs had abnormal karyotypes: case 5 
had a t(9;11)(p22;q23) typical of the M5 subtype; case 6 
had an inv(16)(p13q22), monosomy 7, and trisomy 11; 
and case 9 had a t(8;21)(q22;q22) resulting in a RUNX1–
RUNX1T1 fusion. The fourth AML had an apparently 
normal karyotype (case 7). FISH analysis revealed that 
neither case 6 nor case 7 had any rearrangements of 
KMT2A, whereas case 5 had a rearranged KMT2A allele 
(figure 3B). Nucleotide sequence analysis revealed that 
case 8 (AML) had an FLT3 internal tandem duplication 
mutation and an exon 12 NPM1 mutation (data not 
shown).
Genomic profiling
Genome-wide arrayCGH yielded analysable results from 
six of seven leukaemic patients with ophthalmic involve-
ment (table 2), three of which had primary ophthalmic 
lesions (cases 1, 2 and 5). One BCP-ALL (case 1) and one 
AML (case 6) had no CNAs; the four other cases had an 
average of 3.3 CNAs per case (range 1–7) (table 2). One 
homozygous deletion, including the tumour suppressor 
CDKN2A, was detected in a BCP-ALL (case 3) (figure 3C). 
Case 2 (BCP-ALL) had gain of 21q21.1–q22.3, including 
the RUNX1, ERG and ETS2 oncogenes (figure 3D). Inter-
estingly, this case had also gain of a 0.5 Mb segment in 
12p13.2 and a breakpoint in ETV6, consistent with an 
ETV6–RUNX1 gene fusion. There were no high-level 
gene amplifications and no recurrent CNAs.
dIsCussIOn
Here, we present a comprehensive clinical and genomic 
profiling study of nine leukaemias with orbital and/or 
ocular manifestations. Three were primary orbital mani-
festations of the leukaemia, representing all such cases 
histologically analysed in Denmark from 1980 to 2009. 
The remaining six cases had secondary orbital/ocular 
lesions. Four of our patients had BCP-ALL, and five had 
AML, one of which was originally a CLL. Transforma-
tion of CLL to high-grade AML is an uncommon event 
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Figure 3 FISH and arrayCGH analyses of acute leukaemias with ophthalmic manifestations. (A) FISH analysis showing 
a rearranged ETV6 allele (split red and green signals indicated by arrowheads) in a B-cell precursor acute lymphoblastic 
leukaemia (case 3). (B) FISH analysis showing a rearranged KMT2A allele (split red and green signals indicated by arrowheads) 
in a patient with acute myeloid leukaemia FAB M5 and a t(9;11) translocation (case 5). (C) ArrayCGH analysis showing 
homozygous loss of the tumour suppressor gene CDKN2A (arrow) in a B-cell precursor acute lymphoblastic leukaemia (case 
3). (D) ArrayCGH analysis showing gain of 21q21.1–q22.3, including the RUNX1, ERG and ETS2 oncogenes, and loss of the 
terminal end of 21q in a B-cell precursor acute lymphoblastic leukaemia (case 2).
and is associated with a poor prognosis.9 Thus, all nine 
ophthalmic lesions in this study were acute leukaemias.
The average age at diagnosis of our patients with 
primary ophthalmic lesions was 5 years (24.2 years for all 
our patients), and there were similar numbers of males 
and females. The patients with orbital tumours presented 
with proptosis, displacement of the eye and reduced eye 
mobility. Two patients with ocular infiltrations had pain, 
and one also had reduced visual acuity. Notably, none of 
the paediatric patients with primary orbital manifesta-
tions had leukaemic infiltrates in the retina or choroid, 
whereas four of six patients with secondary ophthalmic 
leukaemias had such infiltrates. Taken together, our find-
ings further emphasise the broad clinical spectrum of 
leukaemic lesions that may manifest in the eye or ocular 
region,1 3 4 6 7 10 11 and the need to consider leukaemia 
in the differential diagnosis of patients with proptosis, 
reduced mobility and/or displacement of the eye.1 4 6
The molecular mechanisms by which leukaemic cells 
give rise to extramedullary dissemination remain elusive. 
Thus, it is unclear why certain leukaemias present with 
orbital and/or ocular manifestations. There is, however, 
evidence suggesting that chemokines may be involved in 
organ-specific homing of neoplastic cells.12 Interestingly, 
ALL cells frequently express the chemokine receptors 
CXCR4 and CXCR3 and CLL cells the CXCR4 and CCR7 
receptors.12 There is also a recent report demonstrating 
that α6 integrin, which frequently is overexpressed in 
ALL, interacts with laminin and mediates the migration 
of ALL cells to the central nervous system.13 Further 
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Table 2 ArrayCGH analysis of seven cases of acute leukaemias with ophthalmic manifestations
Case Diagnosis CNA† Cytoband Chromosome region Length (bp)
Number of 
genes Candidate genes
1 BCP-ALL* No CNAs
2 BCP-ALL* Gain 5q33.3 157 399 690–158 503 889 1 104 199 2
  Gain 12p13.2 11 547 615–12 038 149 490 525 2 ETV6
Gain 12q14.3 66 617 004–67 627 932 1 010 928 5
Loss 16p13.3 5 063 719–6 565 236 1 501 517 9
Loss 17q11.2 28 211 019–29 173 479 962 460 16
Gain 21q21.1-q22.3 21 672 155–43 977 574 22 305 419 209 RUNX1, ERG, ETS2
Loss 21q22.3-qter 43 977 575–46 914 745 2 937 170 76
3 BCP-ALL Loss 1pter-p35.23 0–7 329 451 7 329 451 156
Gain 1q21.1-qter 142 764 722–249 250 621 106 485 899 1267
Loss 9p21.3 20 612 727–22 192 890 1 580 163 30 CDKN2A
Loss 11q13.5-qter 75 898 626–135 006 516 59 107 890 493
5 AML
FAB M5*
Loss 20q13.33 59 008 978–60 021 837 1 012 859 5
6 AML
FAB M4
No CNAs
7 AML
FAB M1
Loss 7q21.2–q36.3 92 294 039–156 451 959 64 157 920 618
9 AML
FAM M2
NA
*Primary ophthalmic lesion.
AML, acute myeloid leukaemia; BCP-ALL, B-cell precursor acute lymphoblastic leukaemia; CNA, copy number alteration; NA, not analysable 
because of poor array quality.
studies are, however, needed to elucidate the exact mech-
anisms behind dissemination of acute leukaemias to the 
eye or ocular region.
The three patients with primary leukaemic orbital 
lesions were in complete remission 6, 9 and 18 years, 
respectively, after diagnosis. In previous studies, patients 
with orbital or ocular involvement of leukaemia had 
a poor prognosis and short overall survival since eye 
involvement often indicates recurrent disease.2 3 In our 
patients diagnosed with leukaemia before orbital/ocular 
lesions occurred, the median survival was 1.06 years 
(range, 2 months to 2 years). In a comprehensive study 
from the Children’s Oncology Group including 1459 
paediatric patients with AML, those with involvement of 
orbital and central nervous system sites had a significantly 
better survival than patients with AML outside the central 
nervous system, those with leukaemia in the cerebro-
spinal fluid and those with no extramedullary leukaemia; 
the overall survival of the patients with AML with orbital 
involvement in this study was 92%.14
Cytogenetic data were available from three of four 
BCP-ALLs and four of five AMLs (table 1). Five cases had 
abnormal karyotypes and two had apparently normal 
karyotypes. The cytogenetic aberrations in these cases 
are similar to those in leukaemias without ophthalmic 
manifestations.15 16 FISH analysis revealed ETV6 rear-
rangements in two of three BCP-ALLs (table 1), 
consistent with ETV6-associated translocations. Indeed, 
case 2 had a t(12;21) translocation commonly asso-
ciated with the ETV6–RUNX1 gene fusion seen in 
approximately 25% of paediatric ALLs.17 Patients with 
this fusion usually have a favourable prognosis.17 Simi-
larly, FISH analysis revealed a rearrangement of KMT2A 
in one of three AML samples analysed. This case had a 
t(9;11)(p22;q23) known to result in a KMT2A–MLLT3 
fusion.18 The prognostic significance of the t(9;11) is 
controversial. Recent studies suggest that this translo-
cation carries an intermediate risk.19 20 Our patient with 
the t(9;11) was alive with no evidence of disease 18 years 
after diagnosis.
The genomic profiles of the orbital/ocular leukaemic 
lesions were further characterised by high-resolution 
arrayCGH (table 2). One BCP-ALL and one AML had no 
CNAs; the remaining four cases had rather quiet genomes. 
These findings are consistent with studies of leukaemic 
cells in bone marrow and/or peripheral blood,21–24 and 
with the observation that fusion gene-driven neoplasms 
often have few other genomic alterations.25 Notably, case 
2 had gain of 21q21.1–q22.3, including the RUNX1, ERG 
and ETS2 oncogenes, and case 3 had a 1.5 Mb homozy-
gous deletion in 9p21.3 including the CDKN2A tumour 
suppressor gene. This gene is frequently deleted in 
ALL and is associated with a poor prognosis and a poor 
response to treatment.26 27
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MYB encodes a transcription factor that is important 
in the control of cell division, apoptosis and differenti-
ation of haematopoietic stem/progenitor cells.28 29 MYB 
is also an oncogene that is activated and overexpressed 
in subsets of acute leukaemias and in certain solid 
tumours.28–31 Here, we show for the first time that MYB 
is overexpressed in ophthalmic lesions in patients with 
acute leukaemias. In these cases, MYB is likely to be an 
important driver of leukaemogenesis and, therefore, also 
a potential therapeutic target. Further studies of MYB in 
acute leukaemias may therefore lead to better treatments 
for these malignancies.
In summary, we present the first comprehensive, inte-
grated clinical, cytogenetic and genomic analyses of nine 
acute leukaemias with ophthalmic manifestations. These 
leukaemias did not differ significantly from those without 
clinically visible ophthalmic manifestations with regard 
to immunophenotype, cytogenetic aberrations, gene 
fusions and CNAs. Awareness of the clinical spectrum of 
leukaemic lesions of the eye or ocular region is important 
to quickly establish the correct diagnosis and commence 
prompt treatment.
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